Trials / Completed
CompletedNCT02061722
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.
[PETDE10] Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington´s Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- CHDI Foundation, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to measure the availability of the PDE10A enzyme in Huntington disease gene expansion carriers (HDGECs) using the recently developed radioligand \[18F\]MNI-659. The study will be cross-sectional, examining HDGECs at different stages of the disease (pre-manifest, stage 1 and stage 2), in comparison with Healthy Controls (HCs). The HDGECs included in this study will be recruited from the large database of the REGISTRY (NCT01590589) or ENROLL-HD (NCT01574053) studies.
Detailed description
The study will be organized in an "adaptive-like" mode. Initially a cohort of 5 HDGECs and 5 HCs will be studied. The data obtained in the first cohort will be analysed and depending on the variability of the data, there will be approximately 10 HDGECs and an equal number of HCs in the second cohort and the size of the third cohort may be altered to in total include approximately 45 HDGECs and an equal number of HCs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | PET Imaging with [18F]MNI-659 | The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected. The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%. The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2014-02-13
- Last updated
- 2016-06-01
Locations
8 sites across 4 countries: Denmark, Netherlands, Norway, Sweden
Source: ClinicalTrials.gov record NCT02061722. Inclusion in this directory is not an endorsement.